This Article Full Text Full Text (PDF) All Versions of this Article: 50/4/715    most recent HYPERTENSIONAHA.107.094235v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hermida, R. C. Articles by Calvo, C. Search for Related Content PubMed PubMed Citation Articles by Hermida, R. C. Articles by Calvo, C. Related Collections Clinical Studies

(Hypertension. 2007;50:715.)
© 2007 American Heart Association, Inc.

XVIIth Scientific Meeting of the Inter-American Society of Hypertension

Comparison of the Efficacy of Morning Versus Evening Administration of Telmisartan in Essential Hypertension

Ramón C. Hermida; Diana E. Ayala; José R. Fernández; Carlos Calvo

From the Bioengineering and Chronobiology Laboratories (R.C.H., D.E.A., J.R.F.), University of Vigo, Campus Universitario, Vigo, Spain; and the Hypertension and Vascular Risk Unit (C.C.), Hospital Clínico Universitario, Santiago de Compostela, Spain.

Correspondence to Ramón C. Hermida, Bioengineering and Chronobiology Labs, E.T.S.I. Telecomunicación, Campus Universitario, Vigo (Pontevedra) 36200, Spain. E-mail rhermida{at}uvigo.es

Valsartan administration at bedtime as opposed to on wakening improves the sleep time–relative blood pressure decline toward a more dipper pattern without loss in 24-hour efficacy. Yet to be determined is whether this administration time-dependent efficacy is a class-related feature, characteristic of all angiotensin receptor blockers or specific only to valsartan. Terminal half-life is a major difference between angiotensin receptor blockers, being largest (24 hours) for telmisartan. This trial investigated the administration time-dependent antihypertensive efficacy of telmisartan. We studied 215 patients with hypertension (114 men and 101 women), 46.4±12.0 years of age, randomly assigned to receive telmisartan (80 mg/d) as a monotherapy either on awakening or at bedtime. Blood pressure was measured for 48 hours before and after 12 weeks of treatment. The significant blood pressure reduction after treatment was similar for both groups. Bedtime administration of telmisartan, however, was more efficient than morning dosing in reducing the nocturnal blood pressure mean. The sleep time–relative blood pressure decline was slightly reduced after telmisartan on awakening but significantly increased with bedtime dosing, thus reducing the prevalence of nondipping from baseline by 76%. Telmisartan administered at bedtime, as opposed to morning dosing, improved the sleep time–relative blood pressure decline toward a more dipper pattern without loss in 24-hour efficacy. Nocturnal BP regulation is significantly better achieved with bedtime dosing of telmisartan. Results from this prospective trial suggest that these beneficial features of bedtime dosing may be class related for angiotensin receptor blockers. These results should be taken into account when prescribing this class of antihypertensive medication for treatment of essential hypertension.

Key Words: telmisartan • essential hypertension • ambulatory blood pressure monitoring • circadian rhythm • chronotherapy • dipper • nondipper • angiotensin receptor blockers

This article has been cited by other articles:

				R. C. Hermida and D. E. Ayala Chronotherapy With the Angiotensin-Converting Enzyme Inhibitor Ramipril in Essential Hypertension: Improved Blood Pressure Control With Bedtime Dosing Hypertension, July 1, 2009; 54(1): 40 - 46. [Abstract] [Full Text] [PDF]

				J. Ishikawa, D. J. Carroll, S. Kuruvilla, J. E. Schwartz, and T. G. Pickering Changes in Home Versus Clinic Blood Pressure With Antihypertensive Treatments: A Meta-Analysis Hypertension, November 1, 2008; 52(5): 856 - 864. [Abstract] [Full Text] [PDF]

				G. Grassi, F. Quarti-Trevano, and G. Mancia Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 66 - 74. [Abstract] [PDF]